146 related articles for article (PubMed ID: 38265977)
1. Effects of orally administered crofelemer on the incidence and severity of neratinib-induced diarrhea in female dogs.
Guy M; Teixeira A; Shrier A; Meschter C; Bolognese J; Chaturvedi P
PLoS One; 2024; 19(1):e0282769. PubMed ID: 38265977
[TBL] [Abstract][Full Text] [Related]
2. Crofelemer for the Management of Neratinib-Associated Diarrhea in Patients With HER2+ Early-Stage Breast Cancer.
Jacob S; Johnson M; Roque B; Quintal L; Rugo HS; Melisko M; Chien AJ
Clin Breast Cancer; 2023 Oct; 23(7):721-728. PubMed ID: 37474374
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of crofelemer for noninfectious diarrhea in HIV-seropositive individuals (ADVENT trial): a randomized, double-blind, placebo-controlled, two-stage study.
Macarthur RD; Hawkins TN; Brown SJ; Lamarca A; Clay PG; Barrett AC; Bortey E; Paterson C; Golden PL; Forbes WP
HIV Clin Trials; 2013; 14(6):261-73. PubMed ID: 24334179
[TBL] [Abstract][Full Text] [Related]
4. Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer.
Chan A; Ruiz-Borrego M; Marx G; Chien AJ; Rugo HS; Brufsky A; Thirlwell M; Trudeau M; Bose R; García-Sáenz JA; Egle D; Pistilli B; Wassermann J; Cheong KA; Schnappauf B; Semsek D; Singer CF; Foruzan N; DiPrimeo D; McCulloch L; Hurvitz SA; Barcenas CH
Breast; 2023 Feb; 67():94-101. PubMed ID: 36702070
[TBL] [Abstract][Full Text] [Related]
5. HALT-D: A Phase II Evaluation of Crofelemer for the Prevention and Prophylaxis of Diarrhea in Patients With Breast Cancer on Pertuzumab-Based Regimens.
Gao JJ; Tan M; Pohlmann PR; Swain SM
Clin Breast Cancer; 2017 Feb; 17(1):76-78. PubMed ID: 27692565
[TBL] [Abstract][Full Text] [Related]
6. A double-blind, randomized, multiple-dose, parallel-group study to characterize the occurrence of diarrhea following two different dosing regimens of neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor.
Abbas R; Hug BA; Leister C; Sonnichsen D
Cancer Chemother Pharmacol; 2012 Jul; 70(1):191-9. PubMed ID: 22418773
[TBL] [Abstract][Full Text] [Related]
7. Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial.
Barcenas CH; Hurvitz SA; Di Palma JA; Bose R; Chien AJ; Iannotti N; Marx G; Brufsky A; Litvak A; Ibrahim E; Alvarez RH; Ruiz-Borrego M; Chan N; Manalo Y; Kellum A; Trudeau M; Thirlwell M; Garcia Saenz J; Hunt D; Bryce R; McCulloch L; Rugo HS; Tripathy D; Chan A;
Ann Oncol; 2020 Sep; 31(9):1223-1230. PubMed ID: 32464281
[TBL] [Abstract][Full Text] [Related]
8. Effect of crofelemer extract on severity and consistency of experimentally induced enterotoxigenic Escherichia coli diarrhea in newborn Holstein calves.
Teixeira AG; Stephens L; Divers TJ; Stokol T; Bicalho RC
J Dairy Sci; 2015 Nov; 98(11):8035-43. PubMed ID: 26298758
[TBL] [Abstract][Full Text] [Related]
9. Crofelemer, a novel antisecretory agent approved for the treatment of HIV-associated diarrhea.
Yeo QM; Crutchley R; Cottreau J; Tucker A; Garey KW
Drugs Today (Barc); 2013 Apr; 49(4):239-52. PubMed ID: 23616951
[TBL] [Abstract][Full Text] [Related]
10. Crofelemer: a review of its use in the management of non-infectious diarrhoea in adult patients with HIV/AIDS on antiretroviral therapy.
Frampton JE
Drugs; 2013 Jul; 73(10):1121-9. PubMed ID: 23807722
[TBL] [Abstract][Full Text] [Related]
11. Crofelemer, a novel agent for treatment of secretory diarrhea.
Crutchley RD; Miller J; Garey KW
Ann Pharmacother; 2010 May; 44(5):878-84. PubMed ID: 20388859
[TBL] [Abstract][Full Text] [Related]
12. Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trial.
Mortimer J; Di Palma J; Schmid K; Ye Y; Jahanzeb M
Breast Cancer Res; 2019 Feb; 21(1):32. PubMed ID: 30813966
[TBL] [Abstract][Full Text] [Related]
13. Crofelemer for the treatment of chronic diarrhea in patients living with HIV/AIDS.
Patel TS; Crutchley RD; Tucker AM; Cottreau J; Garey KW
HIV AIDS (Auckl); 2013; 5():153-62. PubMed ID: 23888120
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients.
Mangel AW; Chaturvedi P
Digestion; 2008; 78(4):180-6. PubMed ID: 19092244
[TBL] [Abstract][Full Text] [Related]
15. Dacomitinib-induced diarrhea: Targeting chloride secretion with crofelemer.
Van Sebille YZA; Gibson RJ; Wardill HR; Ball IA; Keefe DMK; Bowen JM
Int J Cancer; 2018 Jan; 142(2):369-380. PubMed ID: 28921512
[TBL] [Abstract][Full Text] [Related]
16. Noninfectious Diarrhea in HIV Seropositive Individuals: a Review of Prevalence Rates, Etiology, and Management in the Era of Combination Antiretroviral Therapy.
Clay PG; Crutchley RD
Infect Dis Ther; 2014 Dec; 3(2):103-22. PubMed ID: 25388760
[TBL] [Abstract][Full Text] [Related]
17. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
Wong KK; Fracasso PM; Bukowski RM; Lynch TJ; Munster PN; Shapiro GI; Jänne PA; Eder JP; Naughton MJ; Ellis MJ; Jones SF; Mekhail T; Zacharchuk C; Vermette J; Abbas R; Quinn S; Powell C; Burris HA
Clin Cancer Res; 2009 Apr; 15(7):2552-8. PubMed ID: 19318484
[TBL] [Abstract][Full Text] [Related]
18. Targeting neratinib-induced diarrhea with budesonide and colesevelam in a rat model.
Secombe KR; Ball IA; Shirren J; Wignall AD; Finnie J; Keefe D; Avogadri-Connors F; Olek E; Martin D; Moran S; Bowen JM
Cancer Chemother Pharmacol; 2019 Mar; 83(3):531-543. PubMed ID: 30535958
[TBL] [Abstract][Full Text] [Related]
19. The calcium-sensing receptor: A novel target for treatment and prophylaxis of neratinib-induced diarrhea.
Lysyy T; Lalani AS; Olek EA; Diala I; Geibel JP
Pharmacol Res Perspect; 2019 Oct; 7(5):e00521. PubMed ID: 31523434
[TBL] [Abstract][Full Text] [Related]
20. Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial.
Oaknin A; Friedman CF; Roman LD; D'Souza A; Brana I; Bidard FC; Goldman J; Alvarez EA; Boni V; ElNaggar AC; Passalacqua R; Do KTM; Santin AD; Keyvanjah K; Xu F; Eli LD; Lalani AS; Bryce RP; Hyman DM; Meric-Bernstam F; Solit DB; Monk BJ
Gynecol Oncol; 2020 Oct; 159(1):150-156. PubMed ID: 32723675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]